159 related articles for article (PubMed ID: 32986383)
1. Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.
Costa AP; Giraldo PC; Cobucci RN; Consolaro ML; Souza RP; Canário LB; Machado PR; Randall Martins R; Vieira Baptista P; Jr JE; Gonçalves AK
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2799-2804. PubMed ID: 32986383
[TBL] [Abstract][Full Text] [Related]
2. Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.
Sasagawa T; Inoue M; Lehtinen M; Zhang W; Gschmeissner SE; Hajibagheri MA; Finch J; Crawford L
Clin Diagn Lab Immunol; 1996 Jul; 3(4):403-10. PubMed ID: 8807204
[TBL] [Abstract][Full Text] [Related]
3. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
[TBL] [Abstract][Full Text] [Related]
4. Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix.
Ferreira Costa AP; Gonçalves AK; Machado PRL; Souza LBFC; Sarmento A; Cobucci RNO; Giraldo PC; Witkin SS
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2313-2317. PubMed ID: 30141308
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions.
Sasagawa T; Yamazaki H; Dong YZ; Satake S; Tateno M; Inoue M
Int J Cancer; 1998 Feb; 75(4):529-35. PubMed ID: 9466652
[TBL] [Abstract][Full Text] [Related]
6. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.
Bontkes HJ; de Gruijl TD; Walboomers JM; Schiller JT; Dillner J; Helmerhorst TJ; Verheijen RH; Scheper RJ; Meijer CJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():409-417. PubMed ID: 10073701
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy.
Monroy OL; Aguilar C; Lizano M; Cruz-Talonia F; Cruz RM; Rocha-Zavaleta L
J Clin Virol; 2010 Jan; 47(1):43-8. PubMed ID: 19906557
[TBL] [Abstract][Full Text] [Related]
8. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
Rocha-Zavaleta L; Ambrosio JP; Mora-Garcia ML; Cruz-Talonia F; Hernandez-Montes J; Weiss-Steider B; Ortiz-Navarrete V; Monroy-Garcia A
J Gen Virol; 2004 Sep; 85(Pt 9):2643-2650. PubMed ID: 15302958
[TBL] [Abstract][Full Text] [Related]
9. Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia.
Passmore JA; Marais DJ; Sampson C; Allan B; Parker N; Milner M; Denny L; Williamson AL
J Med Virol; 2007 Sep; 79(9):1375-80. PubMed ID: 17607771
[TBL] [Abstract][Full Text] [Related]
10. Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study.
Bierl C; Karem K; Poon AC; Swan D; Tortolero-Luna G; Follen M; Wideroff L; Unger ER; Reeves WC
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S262-8. PubMed ID: 16229879
[TBL] [Abstract][Full Text] [Related]
11. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
[TBL] [Abstract][Full Text] [Related]
12. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.
Marais D; Rose RC; Williamson AL
J Med Virol; 1997 Feb; 51(2):126-31. PubMed ID: 9021543
[TBL] [Abstract][Full Text] [Related]
13. Characterization of IgA response among women with incident HPV 16 infection.
Onda T; Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
Virology; 2003 Jul; 312(1):213-21. PubMed ID: 12890634
[TBL] [Abstract][Full Text] [Related]
14. Seric and local antibodies against a synthetic peptide of HPV16.
Dreyfus M; Baldauf JJ; Ritter J; Obert G
Eur J Obstet Gynecol Reprod Biol; 1995 Apr; 59(2):187-91. PubMed ID: 7657014
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
[TBL] [Abstract][Full Text] [Related]
16. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology.
Rocha-Zavaleta L; Pereira-Suarez AL; Yescas G; Cruz-Mimiaga RM; Garcia-Carranca A; Cruz-Talonia F
Viral Immunol; 2003; 16(2):159-68. PubMed ID: 12828867
[TBL] [Abstract][Full Text] [Related]
17. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
Strickler HD; Schiffman MH; Eklund C; Glass AG; Scott DR; Sherman ME; Wacholder S; Kurman RJ; Manos MM; Schiller JT; Dillner J
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):183-8. PubMed ID: 9138661
[TBL] [Abstract][Full Text] [Related]
18. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.
Wang Z; Hansson BG; Forslund O; Dillner L; Sapp M; Schiller JT; Bjerre B; Dillner J
J Clin Microbiol; 1996 Dec; 34(12):3056-62. PubMed ID: 8940448
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
[TBL] [Abstract][Full Text] [Related]
20. Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia.
Marais DJ; Best JM; Rose RC; Keating P; Soeters R; Denny L; Dehaeck CM; Nevin J; Kay P; Passmore JA; Williamson AL
J Med Virol; 2001 Sep; 65(1):149-54. PubMed ID: 11505457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
